سعر رانيكسا 750مجم 60 قرص ممتد المفعول 2024

Ranolazine 750 mg prolonged-release tablets, box of 60 (3 strips) (Menarini > Medsites, Egypt); antianginal add-on therapy.

• Add-on therapy in adults for the symptomatic treatment of stable angina pectoris in patients inadequately controlled by, or intolerant to, first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).Population: Adultselectronic medicines compendium (emc)

• Common: dizziness, headache, constipation, vomiting, nausea, asthenia.International label, same formulation · electronic medicines compendium (emc)
• Uncommon include anorexia, anxiety, insomnia, confusion, hallucination, syncope, somnolence, tremor, blurred vision, diplopia, vertigo, tinnitus, hypotension, dyspnoea, abdominal pain, dry mouth, dyspepsia, pruritus, muscle cramp, dysuria, haematuria, peripheral oedema, increased blood creatinine/urea and prolonged QTc. Rare include hyponatraemia, pancreatitis, angioedema and acute renal failure.International label, same formulation · electronic medicines compendium (emc)

• Hypersensitivity to ranolazine or any excipient.International label, same formulation · electronic medicines compendium (emc)
• Severe renal impairment (creatinine clearance < 30 ml/min); moderate or severe hepatic impairment.International label, same formulation · electronic medicines compendium (emc)
• Concomitant potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, voriconazole, posaconazole, HIV protease inhibitors, clarithromycin, telithromycin, nefazodone).International label, same formulation · electronic medicines compendium (emc)

• Use caution when increased exposure is expected: moderate CYP3A4 inhibitors, P-gp inhibitors, mild hepatic impairment, mild-moderate renal impairment, elderly, body weight <= 60 kg, moderate-severe heart failure (NYHA III-IV); risk is higher in CYP2D6 poor metabolisers.International label, same formulation · electronic medicines compendium (emc)
• Ranolazine prolongs the QTc interval in a dose-related manner; use caution in congenital or family history of long QT syndrome, acquired QT prolongation, or with drugs affecting QTc.International label, same formulation · electronic medicines compendium (emc)
• Should not be used with CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine, St John's Wort) because of expected lack of efficacy.International label, same formulation · electronic medicines compendium (emc)

• Potent CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors, grapefruit juice)Increase ranolazine exposure (ketoconazole 3.0-3.9-fold AUC); potent inhibitors are contraindicated.electronic medicines compendium (emc)
• Diltiazem, erythromycin, fluconazole (moderate CYP3A4 inhibitors)Diltiazem raises ranolazine steady-state levels 1.5-2.4-fold; careful titration, down-titration may be needed.electronic medicines compendium (emc)
• Verapamil, ciclosporin (P-gp inhibitors)Verapamil increases ranolazine levels 2.2-fold; careful titration recommended.electronic medicines compendium (emc)

• Limited human data; animal studies showed embryotoxicity. Should not be used during pregnancy unless clearly necessary.International label, same formulation · electronic medicines compendium (emc)
• Unknown whether excreted in human milk (excreted in rat milk); should not be used during breast-feeding.International label, same formulation · electronic medicines compendium (emc)

• Ranolazine: Mechanism largely unknown; may act by inhibiting the late sodium current in cardiac cells, reducing intracellular sodium and consequent calcium overload during ischaemia, without depending on changes in heart rate, blood pressure or vasodilation (UK Ranexa SmPC).